CJC-1295 Research: Peer-Reviewed References and Citations

Peer-Reviewed References

The following are peer-reviewed references underpinning all quantitative claims on this site. Every citation includes the original journal publication data and a direct PubMed or official source URL. CJC-1295 human evidence rests primarily on two randomized controlled trials (Teichman 2006, Ionescu 2006) conducted in a combined n=24 healthy adults over a maximum 49-day period. Additional context citations cover the ipamorelin selectivity literature, GH-class body-composition data (tesamorelin), and the GHRH-R signaling review (Halmos 2025).

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. DOI: 10.1210/jc.2005-1536. PubMed ↗
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID: 17018654. DOI: 10.1210/jc.2006-1702. PubMed ↗
3. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. PMID: 15817669. DOI: 10.1210/en.2004-1286. PubMed ↗
4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-4. PMID: 16822960. DOI: 10.1152/ajpendo.00201.2006. PubMed ↗
5. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822. DOI: 10.1530/eje.0.1390552. PubMed ↗
6. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6. PMID: 10496658. DOI: 10.1023/a:1018955126402. PubMed ↗
7. Norman C, Miles J, Bowers CY, Veldhuis JD. Differential pulsatile secretagogue control of GH secretion in healthy men. Am J Physiol Regul Integr Comp Physiol. 2013;305(4):R378-86. PMID: 23485864. DOI: 10.1152/ajpregu.00069.2013. PubMed ↗
8. Johannsson G, Sverrisdóttir YB, Ellegård L, Lundberg PA, Herlitz H. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab. 2002;87(4):1743-9. PMID: 11932310. DOI: 10.1210/jcem.87.4.8394. PubMed ↗
9. Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22. PMID: 20101189. DOI: 10.1097/QAI.0b013e3181cbdaff. PubMed ↗
10. Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-72. PMID: 11735244. DOI: 10.1054/ghir.2001.0239. PubMed ↗
11. Aagaard NK, Grøfte T, Greisen J, Malmlöf K, Johansen PB, Grønbaek H, Ørskov H, Tygstrup N, Vilstrup H. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009;19(5):426-31. PMID: 19231263. DOI: 10.1016/j.ghir.2009.01.001. PubMed ↗
12. Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025; Online ahead of print. PMID: 39934495. DOI: 10.1007/s11154-025-09952-x. PubMed ↗
13. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. [Adverse events reported in same paper as citation 1.] J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. DOI: 10.1210/jc.2005-1536. PubMed ↗
14. Jetté L, et al. [DAC/no-DAC structural data reported in same paper as citation 3.] Endocrinology. 2005;146(7):3052-8. PMID: 15817669. DOI: 10.1210/en.2004-1286. PubMed ↗
15. Jetté L, et al. [DPP-IV resistance and sermorelin half-life comparative data — same paper as citation 3.] Endocrinology. 2005;146(7):3052-8. PMID: 15817669. DOI: 10.1210/en.2004-1286. PubMed ↗
16. U.S. Food and Drug Administration Pharmacy Compounding Advisory Committee. Bulk drug substances nominated for 503A inclusion — December 2024 meeting. FDA Docket FDA-2024-N-4777. 2024. FDA.gov ↗
17. Jetté L, et al. [Oral bioavailability inference from MW and SC route — same paper as citation 3.] Endocrinology. 2005;146(7):3052-8. PMID: 15817669. DOI: 10.1210/en.2004-1286. PubMed ↗
18. Ionescu M, Frohman LA. [GH suppression absence and pulsatility preservation — same paper as citation 2.] J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID: 17018654. DOI: 10.1210/jc.2006-1702. PubMed ↗
19. Teichman SL, et al. [HPG axis not measured; no testosterone data — same paper as citation 1.] J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. DOI: 10.1210/jc.2005-1536. PubMed ↗
20. Ionescu M, Frohman LA. [MK-677 vs CJC-1295 comparison context — same paper as citation 2.] J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID: 17018654. DOI: 10.1210/jc.2006-1702. PubMed ↗
21. Various authors. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. ScienceDirect (in press 2026). PMID: 41545261. PubMed ↗